Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles

John M. Gregson, Daniel F. Freitag, Praveen Surendran, Nathan O. Stitziel, Rajiv Chowdhury, Stephen Burgess, Stephen Kaptoge, Pei Gao, James R. Staley, Peter Willeit, Sune F. Nielsen, Muriel Caslake, Stella Trompet, Linda M. Polfus, Kari Kuulasmaa, Jukka Kontto, Markus Perola, Stefan Blankenberg, Giovanni Veronesi, Francesco GianfagnaSatu Männistö, Akinori Kimura, Honghuang Lin, Dermot F. Reilly, Mathias Gorski, Vladan Mijatovic, Patricia B. Munroe, Georg B. Ehret, Alex Thompson, Maria Uria-Nickelsen, Anders Malarstig, Abbas Dehghan, Thomas F. Vogt, Taishi Sasaoka, Fumihiko Takeuchi, Norihiro Kato, Yoshiji Yamada, Frank Kee, Martina Müller-Nurasyid, Jean Ferrières, Dominique Arveiler, Philippe Amouyel, Veikko Salomaa, Eric Boerwinkle, Simon G. Thompson, Ian Ford, J. Wouter Jukema, Naveed Sattar, Chris J. Packard, Abdulla Al Shafi Majumder, Dewan S. Alam, Panos Deloukas, Heribert Schunkert, Nilesh J. Samani, Sekar Kathiresan, Børge G. Nordestgaard, Danish Saleheen, Joanna M.M. Howson, Emanuele Di Angelantonio, Adam S. Butterworth, John Danesh

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Genetic invalidation of Lp-PLA<sub>2</sub> as a therapeutic target: Large-scale study of five functional Lp-PLA<sub>2</sub>-lowering alleles'. Together they form a unique fingerprint.

Medicine & Life Sciences